tbuckley/cabot-search huggingface dataset:
Interferon-gamma (INFG), an important marker of response to immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) and melanoma patients.
Authors: Niki Karachaliou, Guillermo Crespo, Erika Aldeguer, Ana Drozdowskyj, Ana Gimenez Capitan, Cristina Teixido, Miguel Angel Molina-Vila, Santiago Viteri Ramirez, Daniela Morales-Espinosa, Maria de los Llanos Gil, Maria Gonzalez-Cao, Salvador Martin Algarra, Elisabeth Pérez-Ruiz, Ivan Marquez Rodas, Delvys Rodriguez-Abreu, Remei Blanco, Teresa Puertolas, Maria Angeles Royo, Rafael Rosell
Journal: Journal of Clinical Oncology (2017)

11504 Background: PD-L1 can be induced by oncogenic signals or up-regulated via INFG in a STAT1- and NFκB-dependent manner. STAT3 opposes STAT1-mediated anti-tumor immune responses. I kappa B kinase epsilon (IKBKE) is an interferon signaling inducer. We explored whether INFG expression in pre-treatment tumors is associated with to the efficacy of ICB in NSCLC and melanoma patients. The role of inflammation-associated transcription factors STAT3, IKBKE and STAT1 was also examined. Methods: Total RNA from 17 NSCLC and 21 melanoma patients, was analyzed by qRT-PCR. INFG, STAT3, IKBKE, STAT1 and PD-L1 mRNA were examined. PD-L1 protein expression in tumor and immune cells was evaluated (Ventana SP142 assay). Progression free survival (PFS) and overall survival (OS) were estimated. Results: 17 previously treated NSCLC patients received nivolumab; 71% lung adenocarcinoma, 71% male, 53% smokers, 35% KRAS mutant, 88% EGFR wild-type (wt). 21 previously treated melanoma patients received pembrolizumab; 67% male, 67% BRAF wt. PFS to nivolumab was significantly longer in NSCLC patients with high vs. low INFG expression (5.12 vs. 2mo, p = 0.0124). PFS to pembrolizumab was significantly longer in melanoma patients with high vs. low INFG expression (4.99 vs. 1.86mo, p = 0.0099). Significantly longer OS was observed for melanoma patients with high vs. low INFG expression (not reached vs. 3.10mo p = 0.0183). There was a trend for longer OS for NSCLC patients with high vs. low INFG expression (10.15 vs. 4.86mo, p = 0.0687). The other gene levels and PD-L1 protein levels in tumor and immune cells did not affect the outcome to ICB. IKBKE was positively correlated with INFG and PD-L1 expression (NSCLC Spearman’s ρ = 0.58 and 0.65; melanoma Spearman’s ρ = 0.61 and 0.59), and STAT3 expression was loosely anticorrelated with PD-L1 expression (NSCLC Spearman’s ρ = −0.21; melanoma Pearson’s ρ = −0.01). Conclusions: INFG is an important marker for qRT-PCR mediated prediction of response to ICB in NSCLC and melanoma patients. Further research is warranted in order to validate that INFG is more accurate than PD-L1.
Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target
Authors: Anatoliy I. Masyuk, Tatyana V. Masyuk, Maria J. Lorenzo Pisarello, Jingyi (Francess) Ding, Lorena Loarca, Bing Q. Huang, Nicholas F. LaRusso
Journal: Hepatology (2017)

Polycystic liver disease (PLD) is a group of genetic disorders with limited treatment options and significant morbidity. Hepatic cysts arise from cholangiocytes exhibiting a hyperproliferative phenotype. Considering that hyperproliferation of many cell types is associated with alterations in autophagy, we hypothesized that autophagy is altered in PLD cholangiocytes, contributes to hepatic cystogenesis, and might represent a potential therapeutic target. We employed functional pathway cluster analysis and next-generation sequencing, transmission electron microscopy, immunofluorescence confocal microscopy, and western blotting to assess autophagy in human and rodent PLD cholangiocytes. A three-dimensional culture model was used to study the effects of molecular and pharmacologic inhibition of autophagy on hepatic cystogenesis in vitro, and the polycystic kidney disease-specific rat, an animal model of PLD, to study the effects of hydroxychloroquine, a drug that interferes with the autophagy pathway, on disease progression in vivo. Assessment of the transcriptome of PLD cholangiocytes followed by functional pathway cluster analysis revealed that the autophagy-lysosomal pathway is one of the most altered pathways in PLD. Direct evaluation of autophagy in PLD cholangiocytes both in vitro and in vivo showed increased number and size of autophagosomes, lysosomes, and autolysosomes; overexpression of autophagy-related proteins (Atg5, Beclin1, Atg7, and LC3); and enhanced autophagic flux associated with activation of the cAMP-protein kinase A-cAMP response element-binding protein signaling pathway. Molecular and pharmacologic intervention in autophagy with ATG7 small interfering RNA, bafilomycin A1 , and hydroxychloroquine reduced proliferation of PLD cholangiocytes in vitro and growth of hepatic cysts in three-dimensional cultures. Hydroxychloroquine also efficiently inhibited hepatic cystogenesis in the polycystic kidney disease-specific rat.Autophagy is increased in PLD cholangiocytes, contributes to hepatic cystogenesis, and represents a potential therapeutic target for disease treatment. (Hepatology 2018;67:1088-1108).
Clinical and Genetic Risk Prediction of Subsequent CNS Tumors in Survivors of Childhood Cancer: A Report From the COG ALTE03N1 Study
Authors: Xuexia Wang, Can-Lan Sun, Lindsey Hageman, Kandice Smith, Purnima Singh, Sunil Desai, Douglas S. Hawkins, Melissa M. Hudson, Leo Mascarenhas, Joseph P. Neglia, Kevin C. Oeffinger, A. Kim Ritchey, Leslie L. Robison, Doojduen Villaluna, Wendy Landier, Smita Bhatia
Journal: Journal of Clinical Oncology (2017)

Purpose Survivors of childhood cancer treated with cranial radiation therapy are at risk for subsequent CNS tumors. However, significant interindividual variability in risk suggests a role for genetic susceptibility and provides an opportunity to identify survivors of childhood cancer at increased risk for these tumors. Methods We curated candidate genetic variants from previously published studies in adult-onset primary CNS tumors and replicated these in survivors of childhood cancer with and without subsequent CNS tumors (82 participants and 228 matched controls). We developed prediction models to identify survivors at high or low risk for subsequent CNS tumors and validated these models in an independent matched case-control sample (25 participants and 54 controls). Results We demonstrated an association between six previously published single nucleotide polymorphisms (rs15869 [ BRCA2], rs1805389 [ LIG4], rs8079544 [ TP53], rs25489 [ XRCC1], rs1673041 [ POLD1], and rs11615 [ ERCC1]) and subsequent CNS tumors in survivors of childhood cancer. Including genetic variants in a Final Model containing age at primary cancer, sex, and cranial radiation therapy dose yielded an area under the curve of 0.81 (95% CI, 0.76 to 0.86), which was superior ( P = .002) to the Clinical Model (area under the curve, 0.73; 95% CI, 0.66 to 0.80). The prediction model was successfully validated. The sensitivity and specificity of predicting survivors of childhood cancer at highest or lowest risk of subsequent CNS tumors was 87.5% and 83.5%, respectively. Conclusion It is possible to identify survivors of childhood cancer at high or low risk for subsequent CNS tumors on the basis of genetic and clinical information. This information can be used to inform surveillance for early detection of subsequent CNS tumors.
Everolimus-exemestane (EE) vs palbociclib-letrozole (PL) or palbociclib-fulvestrant (PF) in the treatment of metastatic HR+, HER2- breast cancer. An indirect comparison with network meta-analysis
Authors: C. Cherubini, L. Gianni, L. Stocchi, V. Arcangeli, O. Carminati, M. Papi, G. Pasini, M. Fantini, S.V.L. Nicoletti, D. Tassinari
Journal: Annals of Oncology (2017)
Faecal microbiota transplantation donor stools need screening for poliovirus
Authors: Peter Gerald Speck, James G Mitchell
Journal: Gut (2017)

We read with interest the recent report describing faecal microbiota transplantation (FMT) as an effective treatment for certain gastrointestinal diseases, such as Clostridium difficile infection,1 with its high burden and increasing frequency.2 In FMT, donor stools are screened for infectious diseases prior to use.3 Screening protocols are still developing. The protocol of Cammarota et al recognises as risky ‘recent (<6 months) history of vaccination with a live attenuated virus, if there is a possible risk of transmission’.1 We contend that this precaution needs extension to include donors who are chronic poliovirus excreters. …
Prognostic Role of Immunoglobulin G Fragment C Receptor Polymorphisms in Solid Tumors—Reply
Authors: S. Rim Kim, Patrick G. Gavin, Katherine Pogue-Geile
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Sequential therapy with bevacizumab and epidermal growth factor receptor-directed agents for metastatic colorectal carcinoma: A retrospective, registry-based analysis
Authors: T. Buchler, R. Chloupkova, A. Poprach, O. Fiala, I. Kiss, K. Kopeckova, L. Dusek, L. Slavicek, M. Kohoutek, J. Finek, M. Svoboda, L. Petruzelka, B. Melichar
Journal: Annals of Oncology (2017)
Retrospective observational study to evaluate the use of halaven plus trastuzumab for the treatment of HER2(+) metastatic breast cancer (MBC) in Spain: HALATRUST study
Authors: M.J. Echarri González, F. Ayala de la Peña, R. Márquez Vázquez, J.A. García-Saenz, E. Galve Calvo, J.J. Illarramendi Mañas, E. Millastre Bocos, M. Margelí Vila, P. Sánchez Rovira, J.I. Chacón López-Muñiz, P. Cerezuela Fuentes, R. Andrés Conejero, L. Cerrato Crespan, I. Marrodán Ciordia, A. Ocana Fernandez, I. Álvarez López, J.E. Alés Martínez, L. Palomar Abad, L. Orcajo Rincon, J. Rodríguez-Villanueva
Journal: Annals of Oncology (2017)
Role of prephase treatment prior to definitive chemotherapy in diffuse large B -cell lymphoma (DLBCL)
Authors: A. Rudresha, V. Asati, L.C. Kuntegowdanahalli, G. Babu, D. Lokanatha, L.A. Jacob, S. Babu, C.S. Premalata, L. Rajeev, K.N. Lokesh, S.C. Saldanha, R. Patidar
Journal: Annals of Oncology (2017)
Updated results of a phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer
Authors: B. Han, H.S. Kim, D.R. Choi, B.Y. Shim, K.H. Lee, J.W. Kim, J.H. Kim, H.Y. Kim, H. Song, D.Y. Zang
Journal: Annals of Oncology (2017)
Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): Mature results from the phase 3 KEYNOTE-045 trial
Authors: R. de Wit, D.J. Vaughn, Y. Fradet, J-L. Lee, L. Fong, N.J. Vogelzang, M.A. Climent, D.P. Petrylak, T.K. Choueiri, A. Necchi, W.R. Gerritsen, H. Gurney, D.I. Quinn, S. Culine, C.N. Sternberg, Y. Mai, M. Puhlmann, R.F. Perini, J. Bellmunt, D.F. Bajorin
Journal: Annals of Oncology (2017)
Abstract 12788: Adiponectin Modulates the Cardiovascular Risk Associated With Obesity: Results From the Framingham Offspring Study
Authors: Pimjai Anthanont, Yanhua Zhou, Bela F Asztalos, Masumi Ai, Seiko Otokozawa, Katsuyuki Nakajima, Ching-Ti Liu, L. Adrienne Cupples, Ernst J Schaefer
Journal: Circulation (2015)

Objectives: Our objective was to examine the interrelationships of cardiovascular disease (CVD) risk factors with obesity, lipoproteins and their subfractions, markers of glucose homeostasis, and the inflammation markers adiponectin, and C reactive protein (hs-CRP). Methods: We measured fasting plasma lipids, low-density lipoprotein (LDL)-C, small dense LDL-C (sdLDL-C), high-density lipoprotein (HDL)-C, HDL subfractions, triglycerides, glucose, insulin, adiponectin, and hs-CRP in 2,691 male and female participants (median age 58 years) in cycle 6 of the Framingham Offspring Study. We carried out univariate and multivariate statistical analyses. Results: In both men and women the presence of obesity compared to those of normal weight was significantly (P&lt;0.05) associated with: 1) a 60% increase in the prevalence of CVD, 2) a two to three fold higher prevalence of major CVD risk factors (hypertension, diabetes, and low HDL-C &lt; 40 mg/dL), 3) a doubling of plasma levels of hsCRP, insulin, and triglycerides, 4) increased sdLDL-C, and 5) significant decreases in adiponectin and the levels of apoA-I in very large protective α-1 HDL. Surprisingly there was no relationship of obesity with levels of LDL-C in men. By multivariate analysis, in both men and women, adiponectin level emerged as the statistically most important parameter determining the variability of HDL-C and apoA-I levels in very large α-1 HDL, and sdLDL-C, while for systolic blood pressure age was the most important determinant, and for hsCRP levels it was plasma insulin levels. Interestingly over half of obese subjects were not hypertensive or prediabetic, and less than 20% had premature CVD or diabetes. By tertile analysis in obese subjects, low adiponectin was associated with a doubling of the prevalence of diabetes, and significant increases in triglycerides, and sdLDL-C (men only), and significant decreases in HDL-C and apoA-I in large α-1 HDL. Conclusions: Our data indicate that the prevalence of CVD and its risk factors increases with body mass index, and that the level of circulating adiponectin is a significant determinant of cardiovascular risk, especially diabetes prevalence, and levels of LDL and HDL subfractions in obese subjects.
Health-related quality of Life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR)
Authors: A. Vogel, S. Qin, M. Kudo, S. Hudgens, T. Yamashita, J-H. Yoon, L. Fartoux, K. Simon, C. López López, M. Sung, C. Dutcus, S. Kraljevic, T. Tamai, N. Grunow, G. Meier, V. Breder
Journal: Annals of Oncology (2017)
ABOUND.70+: Safety and efficacy of <i>nab</i>-paclitaxel/carboplatin (<i>nab</i>-P/C) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC).
Authors: Corey J. Langer, Eric C. Anderson, Robert M. Jotte, Jonathan Wade Goldman, Daniel Ernest Haggstrom, Matei Paul Socoteanu, David A. Smith, Christopher Dakhil, Kartik Konduri, Edward S. Kim, Teng Jin Ong, Alexandra Sanford, Katayoun Amiri, Jared Weiss
Journal: Journal of Clinical Oncology (2017)

9059 Background: Treatment (tx) of elderly pts with NSCLC is challenging. nab-P/C demonstrated efficacy in a subset of pts with NSCLC ≥ 70 y in a phase III trial. ABOUND.70+ was designed to determine whether a 1-week break can further improve tolerability of nab-P/C in pts ≥ 70 y with NSCLC. Safety and efficacy were evaluated and are reported. Methods: Pts ≥ 70 y with tx-naive locally advanced/metastatic NSCLC were randomized (1:1) nab-P 100 mg/m 2 d 1, 8, 15 + C AUC 6 d 1 q3w (Arm A) or the same nab-P/C dose q3w followed by a 1-week break (Arm B). Primary endpoint: percentage of pts with either grade ≥ 2 peripheral neuropathy (PN) or grade ≥ 3 myelosuppression AEs. Key secondary endpoints: PFS, ORR, OS, for which statistical analyses do not control for type I error ( Pvalues unadjusted). Results: At interim evaluation, the primary endpoint was similar across arms, resulting in early closure of enrollment. In Arms A and B, 71 and 72 pts were randomized; median age was 76 and 75 y, majority of pts were male (57.7% vs 55.6%) and had ECOG PS 1 (70.4% vs 72.2%). There were no differences in histology across tx arms. See table for primary endpoint data. Median number of tx cycles for Arms A and B was 4.0 and 5.5, median cumulative nab-P dose was 875.0 and 1287.5 mg/m 2 , and median weekly dose intensity was 62.0 and 54.1 mg/m 2 . nab-P dose modifications (Arms A and B): ≥ 1 dose reduction in 64.7% and 58.6%, ≥ 1 dose delay in 58.8% and 48.6%, and ≥ 1 missed dose in 80.9% and 72.9%, respectively. Median PFS (Arms A and B) 3.9 vs 7.0 mo (HR 0.49; 95% CI, 0.30 - 0.79; P = 0.003), confirmed ORR 23.9% vs 40.3% ( P = 0.037), and median OS 15.2 vs 16.2 mo (HR 0.76; 95% CI, 0.46 - 1.26; P= 0.292). Conclusions: Incidence of grade ≥ 2 PN or grade ≥ 3 myelosuppression AEs was similar between the 2 nab-P/C schedules in pts ≥ 70 y with advanced NSCLC. There appears to be a signal of improvement in PFS and ORR observed in Arm B, potentially due to increased tx exposure. NCT02151149 Clinical trial information: NCT02151149. [Table: see text]
Vigilância da tuberculose na Região Europeia da OMS em 1995: resultados do estudo de exequibilidade
Authors: A Perrocheau, V Schwoebel, J Veen
Journal: Eurosurveillance (1998)

A avaliacao das modificacoes epidemiologicas da tuberculose (TB) na Europa tem sido limitada pelas diferencas, entre os varios paises, nas definicoes e na qualidade dos sistemas de vigilância (1,2). Em 1996, por forma a normalizar a vigilância da TB entre os paises europeus, foram elaboradas recomendacoes de consenso, incluindo uma definicao de caso comum e um conjunto minimo de variaveis, por um grupo de trabalho estabelecido pela Organizacao Mundial de Saude (OMS) e Uniao Internacional Contra a Tuberculose e Doencas Respiratorias e aprovadas por representantes de 37 paises (3,4).
Breast cancer statistics, 2017, racial disparity in mortality by state
Authors: Carol E. DeSantis, Jiemin Ma, Ann Goding Sauer, Lisa A. Newman, Ahmedin Jemal
Journal: CA A Cancer Journal for Clinicians (2017)

In this article, the American Cancer Society provides an overview of female breast cancer statistics in the United States, including data on incidence, mortality, survival, and screening. Approximately 252,710 new cases of invasive breast cancer and 40,610 breast cancer deaths are expected to occur among US women in 2017. From 2005 to 2014, overall breast cancer incidence rates increased among Asian/Pacific Islander (1.7% per year), non-Hispanic black (NHB) (0.4% per year), and Hispanic (0.3% per year) women but were stable in non-Hispanic white (NHW) and American Indian/Alaska Native (AI/AN) women. The increasing trends were driven by increases in hormone receptor-positive breast cancer, which increased among all racial/ethnic groups, whereas rates of hormone receptor-negative breast cancers decreased. From 1989 to 2015, breast cancer death rates decreased by 39%, which translates to 322,600 averted breast cancer deaths in the United States. During 2006 to 2015, death rates decreased in all racial/ethnic groups, including AI/ANs. However, NHB women continued to have higher breast cancer death rates than NHW women, with rates 39% higher (mortality rate ratio [MRR], 1.39; 95% confidence interval [CI], 1.35-1.43) in NHB women in 2015, although the disparity has ceased to widen since 2011. By state, excess death rates in black women ranged from 20% in Nevada (MRR, 1.20; 95% CI, 1.01-1.42) to 66% in Louisiana (MRR, 1.66; 95% CI, 1.54, 1.79). Notably, breast cancer death rates were not significantly different in NHB and NHW women in 7 states, perhaps reflecting an elimination of disparities and/or a lack of statistical power. Improving access to care for all populations could eliminate the racial disparity in breast cancer mortality and accelerate the reduction in deaths from this malignancy nationwide. CA Cancer J Clin 2017;67:439-448. © 2017 American Cancer Society.
Abstract 17850: Elevated Inflammatory Plasma Biomarkers in Patients With Anderson-Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction
Authors: Haran Yogasundaram, Brendan N Putko, Michel Boutin, Ratnadeep Basu, Marleen E Irwin, Aneal Khan, Christiane Auray-Blais, Michael L West, Gavin Y Oudit
Journal: Circulation (2016)

Introduction: Anderson-Fabry disease (AFD) is a multisystem X-linked recessive lysosomal storage disorder with an estimated global prevalence of 1 in 3000 individuals. AFD is characterized by accum...
Absolute levels of cardiac high-energy phosphate metabolites in human heart failure and left ventricular hypertrophy - Non-invasive measurements by P-31-SLOOP MRS
Authors: M Beer, W Landschuetz, Sandstede Jjw., H Koestler, T Pabst, M Meininger, M Von Kienlin, M Horn, K Harre, W Kenn, D Hahn, S Neubauer
Journal: Circulation (2000)
Physician initiated cancer screening discussions and patient intention to engage in screening behavior
Authors: S. W. Gray, N. Wong, B. Kelly, A. Romantan, S. Ramirez, T. Fraze, A. Smith-McLallen, K. Armstrong, J. Schwartz, R. Hornik
Journal: Journal of Clinical Oncology (2007)

1528 Background: Cancer screening for colon, breast, and prostate cancer remains underutilized. Physician (MD)-patient discussions of screening are common but the impact of these discussions is unknown. Methods: 2489 40–70 year old subjects completed a national survey of cancer prevention information acquisition and decision making (median age 53, 49% male, 77% white, 59% married, 61% some college). Subjects reported whether their MD initiated discussions (MDID) about colonoscopy, mammography, &amp; PSA within the past year. Age eligible subjects were “non-routine screeners” (NRS: never screened or colonoscopy &gt;10 yrs, mammography &gt;2 yrs or PSA&gt;2 yrs prior) or “routine screeners” (RS).The endpoint was intention to screen when next eligible. Results: 46%, 75% and 60% of subjects reported intentions to obtain colonoscopy, mammography and/or PSA. Logistic regression was used to determine the association between MDID and intentions to screen controlling for sociodemographics and recency of screening. For colonoscopy and mammography, MDID was significantly associated with intention to screen for NRS but not RS groups; the opposite was true for PSA. For the NRS group: comparing those saying no versus yes to MDID, intentions were 15% vs. 43% for colonoscopy, 29% to 61% for mammography (RS: 85% vs. 91% and 82% vs. 85%). For PSA, NRS: 46% vs.52% but RS group 65% vs. 85%. All interactions (screening by MDID) were significant, p&lt;.001. Conclusions: Given high intentions to undergo colon and breast cancer screening among patients who have been screened routinely, physician discussion preferentially increases intentions for colon and breast cancer screening among patients who are not routinely undergoing the screening test. Conversely, physician discussion preferentially influences prostate cancer screening intentions among patients who have been screened in the past two years- perhaps because men who have not undergone screening are more resolved in their decision not to screen. These results define subgroups of patients where physician attention may have the greatest impact on screening adherence. No significant financial relationships to disclose.
Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study
Authors: M. Provencio Pulla, A. Santoro, L. Mollica, S. Leppä, G. Follows, G. Lenz, W.S. Kim, A. Nagler, P. Panayiotidis, J. Demeter, M. Özcan, M. Kosinova, K. Bouabdallah, F. Morschhauser, T. Ishida, L. Huang, J. Garcia-Vargas, B.H. Childs, P.L. Zinzani, M. Dreyling
Journal: Annals of Oncology (2017)